All In Biotech

Drug Trial Radar · NCT05104775

A Study of GNC-035, a Tetra-specific Antibody, in Participants With Relapsed/Refractory Hematologic Malignancy

An Open-Label, Multi-Center, Phase I Study to Evaluate the Safety, Tolerability,Pharmacokinetic/Pharmacodynamics and Anti-tumor Activity of Tetra-specific Antibody GNC-035 in Participants With Relapsed/Refractory Hematologic Malignancy and Locally Advanced or Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Sep 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

33

Actual

Start

Feb 9, 2022

Primary completion

Dec 2025

Study completion Dec 2025

Sponsor

Sponsor type
Industry
Collaborators
SystImmune Inc.
First posted
Nov 3, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this study, the safety, tolerability and preliminary effectiveness of GNC-035 in patients with relapsed/refractory hematologic malignancies will be investigated to assess the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) or maximum administered dose (MAD) for MTD is not reached of GNC-035.

Conditions

  • Hematologic Malignancies

Interventions

  • GNC-035Drug

    Administration by intravenous infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. DLTTime frame: Up to 2 weeks
  2. MTD or MADTime frame: Up to 2 weeks
  3. TEAETime frame: Up to 2 years
  4. The recommended dose for future clinical studyTime frame: Up to 2 weeks
  5. RP2DTime frame: Up to 2 years

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Guangzhou First People's Hospital

    Guangzhou, Guangdong, China

  • Affiliated Hospital of Guizhou Medical University

    Guiyang, Guizhou, China

  • The Fourth Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

  • Union Hospital Tongji Medical College Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Shengjing Hospital of China Medical University

    Shenyang, Liaoning, China

  • Ruijin Hospital, Shanghai Jiaotong University School of Medicine

    Shanghai, Shanghai Municipality, China

  • The Second People's Hospital of Yibin

    Yibin, Sichuang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.